Crossmark

High expression of cystine–glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma

Crossref DOI link: https://doi.org/10.1007/s11060-018-2785-9

Published Online: 2018-02-05

Published Print: 2018-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sørensen, Mai Froberg

Heimisdóttir, Sólborg Berglind

Sørensen, Mia Dahl

Mellegaard, Casper Schau

Wohlleben, Helle

Kristensen, Bjarne Winther

Beier, Christoph Patrick https://orcid.org/0000-0001-8268-1492
Funding

Funding for this research was provided by:

Region of Southern Denmark
License Information

Text and Data Mining valid from 2018-02-05
More Information

Article History

Received: 20 November 2017

Accepted: 31 January 2018

First Online: 5 February 2018

Compliance with ethical standards

:

: CPB has also served as an advisory board member for UCB and EISAI, received speakers honoraries from UCB, EISAI, and the Danish Epilepsy Association, and research support from UCB, EISAI, Novartis, and Pfizer. The other authors have no conflicts of interest.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.